These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1653578)
21. [Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk]. Strano A; Novo S; Notarbartolo A; Davì G; Abrignani MG; Alaimo G; Averna MR; Barbagallo CM; Marino G Cardiologia; 1989 Dec; 34(12):1027-33. PubMed ID: 2634479 [TBL] [Abstract][Full Text] [Related]
22. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study]. Ghizzoni G; Rusconi C; Faggiano P; Sabatini T; Oneglia C; Gardini A Minerva Cardioangiol; 1993 Mar; 41(3):105-9. PubMed ID: 8510811 [TBL] [Abstract][Full Text] [Related]
23. Cryptic adenosine triphosphatase activities in plasma membranes of CCl4-cirrhotic rats. Its modulation by changes in cholesterol/phospholipid ratios. Yahuaca P; Amaya A; Rojkind M; Mourelle M Lab Invest; 1985 Nov; 53(5):541-5. PubMed ID: 2997543 [TBL] [Abstract][Full Text] [Related]
24. Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia. Levy Y; Leibowitz R; Aviram M; Brook JG; Cogan U Br J Clin Pharmacol; 1992 Nov; 34(5):427-30. PubMed ID: 1467138 [TBL] [Abstract][Full Text] [Related]
25. Anti-inflammatory and hypolipemic effects in vitro of simvastatin comparing to epicatechin in patients with type-2 hypercholesterolemia. Franiak-Pietryga I; Koter-Michalak M; Broncel M; Duchnowicz P; Chojnowska-Jezierska J Food Chem Toxicol; 2009 Feb; 47(2):393-7. PubMed ID: 19084570 [TBL] [Abstract][Full Text] [Related]
26. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. Pappu AS; Bacon SP; Illingworth DR J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170 [TBL] [Abstract][Full Text] [Related]
28. [Therapy of hypercholesterolemia and hypertriglyceridemia. Comparison of the lipid-lowering effect of simvastatin and tiadenol]. Serra T; Gavelli MS; Vitaliano E; Santini G; Catalano A; Rossi FG; Tozzi J; Caridis R; Guarini G Clin Ter; 1990 Mar; 132(5):307-13. PubMed ID: 2139833 [TBL] [Abstract][Full Text] [Related]
29. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Branchi A; Rovellini A; Fiorenza AM; Sommariva D Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386 [TBL] [Abstract][Full Text] [Related]
30. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties. Uyuklu M; Meiselman HJ; Baskurt OK Clin Hemorheol Microcirc; 2007; 36(1):25-33. PubMed ID: 17211059 [TBL] [Abstract][Full Text] [Related]
31. [Simvastatin in the treatment of hypercholesterolemia]. Cigala O; Pancallo MT; Della Valle M; Marasco A; Malarbi AL Clin Ter; 1991 Jun; 137(5):333-7. PubMed ID: 1832606 [TBL] [Abstract][Full Text] [Related]
32. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences]. Geisel J; Oette K; Burrichter H Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032 [TBL] [Abstract][Full Text] [Related]
33. [Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance]. Panuccio D; Trabatti MR; Romani A Clin Ter; 1994 May; 144(5):419-24. PubMed ID: 7924180 [TBL] [Abstract][Full Text] [Related]
34. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia]. Darioli R; Bovet P; Brunner HR; Bercher L Schweiz Med Wochenschr; 1990 Jan; 120(4):85-91. PubMed ID: 2305221 [TBL] [Abstract][Full Text] [Related]
36. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Eckernäs SA; Roos BE; Kvidal P; Eriksson LO; Block GA; Neafus RP; Haigh JR Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404 [TBL] [Abstract][Full Text] [Related]
37. [Efficacy and safety of simvastatin, a new cholesterol-lowering drug]. Mol MJ; Stuyt PM; Stalenhoef AF Ned Tijdschr Geneeskd; 1989 Feb; 133(7):362-6. PubMed ID: 2927555 [TBL] [Abstract][Full Text] [Related]
38. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426 [TBL] [Abstract][Full Text] [Related]
39. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. Lijnen P; Celis H; Fagard R; Staessen J; Amery A J Hypertens; 1994 Jan; 12(1):59-64. PubMed ID: 8157945 [TBL] [Abstract][Full Text] [Related]
40. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia. Mol MJ; Stuyt PM; Demacker PN; Stalenhoef AF Neth J Med; 1990 Apr; 36(3-4):182-90. PubMed ID: 2355995 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]